Kailera Therapeutics Prices $625M IPO

Got story updates? Submit your updates here. ›

Kailera Therapeutics, an advanced clinical-stage biotechnology company focused on obesity treatments, announced the pricing of its initial public offering of 39,062,500 shares of common stock at $16 per share. The IPO is expected to raise $625 million in gross proceeds, with an additional 30-day option for underwriters to purchase up to 5,859,375 more shares.

Why it matters

Kailera's IPO represents a significant milestone for the biotech industry, as the company aims to develop innovative obesity therapies at a time when obesity rates continue to rise globally. The successful IPO also highlights investor appetite for promising new treatments in this therapeutic area.

The details

All of the shares in the IPO are being offered by Kailera Therapeutics. The company's common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol 'KLRA' on April 17, 2026, with the offering closing on April 20, 2026. J.P. Morgan, Jefferies, Leerink Partners, TD Cowen and Evercore ISI are acting as joint book-running managers, while William Blair is the lead manager.

• Kailera filed its S-1 registration statement on April 16, 2026.
• The IPO is expected to price on April 16, 2026.
• Kailera's stock is expected to begin trading on April 17, 2026.
• The IPO is expected to close on April 20, 2026.

What’s next

Kailera's stock is expected to begin trading on the Nasdaq Global Select Market on April 17, 2026, and the IPO is expected to close on April 20, 2026, subject to customary closing conditions.